NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q2 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 92.1%, down 7.9 pp year over year. Over 3 fiscal years it narrowed by 0.3 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
100.0%+16.4 pp QoQ
Last fiscal yearDec 2025
99.7%-0.3 pp YoY
LTMJun 2026
92.1%-7.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year-0.3 pp——
3 years-0.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
99.7%
Year-over-year change
-0.3pp

Gross Margin vs competitors

How NAMS compares with its peers on the latest reported figures

  • NAMS's LTM Jun 2026 gross margin of 92.1% is the 3rd highest of the 6 companies compared; the peer median is 91.5%.
  • Its year-over-year change of -7.9 pp is the 4th highest of 5, against a peer median of -2.7 pp.
  • Over three fiscal years its change of -0.3 pp compares with a peer median of +4.8 pp.
NAMS Competitors Peer median
Gross Margin for NAMS and competitors
Company Period LTM level YoY 3-year change
BIOABioAge Labs, Inc.LTM Mar 202699.4% -0.6 pp—
ATHEAlterity Therapeutics LimitedFY202597.7% +3.0 pp+4.8 pp
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 202692.1% -7.9 pp-0.3 pp
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 202691.5% -4.8 pp—
SEPNSepterna, Inc.LTM Sep 202679.9% -20.1 pp—
DNLIDenali Therapeutics Inc.LTM Jun 2026-61.0% ——
AMLXAmylyx Pharmaceuticals, Inc.FY2025— ——
VKTXViking Therapeutics, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding NAMS) 91.5%-2.7 pp+4.8 pp

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0102.69M14.09M45.56M22.5M
Cost of Revenue000059K
Gross Profit0102.69M14.09M45.56M22.44M
Gross Margin—100.0%100.0%100.0%99.7%
Research & Development28.97M86.74M159.42M151.41M141.83M
Selling, General & Admin5.68M19.51M37.63M70.45M106.3M
Operating Expenses34.98M106.25M197.06M221.85M248.13M
Depreciation & Amortization5K9K49K113K220K
EBITDA(41.37M)(22.34M)(176.86M)(241.49M)(242.33M)
EBITDA Margin—-21.8%-1255.2%-530.0%-1076.9%
Operating Income(34.98M)(3.56M)(182.97M)(176.29M)(225.68M)
Operating Margin—-3.5%-1298.6%-386.9%-1002.9%
Interest Income0010.22M16.88M27.59M
Interest Expense411K287K6.8M00
Other Income / Expenses(6.81M)(19.08M)6.06M(65.31M)21.86M
Income Before Tax(41.79M)(22.63M)(176.91M)(241.6M)(203.82M)
Pre-Tax Margin—-22.0%-1255.6%-530.3%-905.7%
Income Tax Expense0027K(1K)0
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Net Margin—-22.0%-1255.8%-530.3%-905.7%
EPS (Basic)(3.34)(1.19)(2.15)(2.56)(1.75)
EPS (Diluted)(3.34)(1.19)(2.15)(2.56)(1.75)
Weighted Avg Shares17.75M18.97M82.16M94.36M114.4M
Weighted Avg Shares (Diluted)17.75M18.97M82.16M94.36M114.4M

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.